Leuprolide Completed Phase 3 Trials for Uterine Leiomyomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00740831PGL4001 Versus GnRH-agonist in Uterine Myomas
NCT02655237A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids